Make informed decisions about your ideal patient cohort
Quickly create and iterate reports to gain insights on ideal patient cohorts in minutes. Access de-identified all-payor claims data to explore patient populations and make informed commercialization decisions. Adjust search parameters, refine analyses and target specific disease states in real-time to find the answers you’ve been looking for—and even those you haven’t.
Find your ideal patient population
Watch the video to see why Latitude Reporting is changing the way businesses discover and understand their ideal patient cohorts and how it can help you make more informed commercialization decisions.
Discover the answers you need
Latitude Reporting gives you an intuitive, iterative platform that can be used to:
Create customized patient cohorts
Quickly build and explore patient populations tuned to your desired search parameters and criterion. Gain the insights you need to navigate market complexity and answer your most critical business questions.Try now
Analyze and learn
Leverage detailed intelligence from provider, patient, geographical and payor perspectives in a single, integrated view of your ideal cohort(s). Refine your search criterion to find even very targeted patient populations.Try now
Build claims data reports
Customize report templates to focus on the information most important to you. Or use the report builder to create a new report by simply choosing a cohort and selecting report type and timeframe.Try now
Get a clearer picture
With Latitude Reporting you can:
Accelerate your go-to-market
Latitude Reporting enables you to:
See the big picture
Latitude Reporting provides even greater value when integrated with other data products to create comprehensive industry solutions and use-case specific solutions. Latitude Reporting complements other data products as part of these solutions:
Just starting your commercialization journey?
Latitude Discovery enables pre-commercial biopharma and medical device organizations to quickly assess potential market opportunities associated with therapy development for granular patient cohorts.